Quantification of plasma APOE4 with a novel automated Lumipulse immunoassay enables the identification of homozygous and heterozygous APOE ε4 carrier status
This novel immunoassay demonstrates excellent and potential for faster results could offer advantages in clinical practice, particularly for AD therapy eligibility evaluation. However, further validation in larger, diverse cohorts is necessary before considering widespread clinical implementation.
Authors
- Stefania Moz (ORCID: https://orcid.org/0000-0002-7485-520X)
- Martina Montagnana (ORCID: https://orcid.org/0000-0001-8999-0001)
- Annachiara Cagnin (ORCID: https://orcid.org/0000-0002-0635-4884)
- A. Codemo
- Angelo Antonini (ORCID: https://orcid.org/0000-0003-1040-2807)
- Giulia Musso (ORCID: https://orcid.org/0000-0002-7748-773X)
- Carlo‐Federico Zambon (ORCID: https://orcid.org/0000-0002-4244-879X)
- Chiara Cosma (ORCID: https://orcid.org/0000-0002-0678-0277)
- Carlo Gabelli
- Maurizio Corbetta (ORCID: https://orcid.org/0000-0001-8295-3304)
- Filippo Navaglia
Institutions
- University of Padua (IT)
- Santa Maria Nuova Hospital (IT)
- IRCCS San Camillo Hospital (IT)
Publication Details
- Journal
- Clinica Chimica Acta
- Published
- 2025-10-12
- DOI
- https://doi.org/10.1016/j.cca.2025.120659
- Citations
- 1
- Primary Topic
- Asthma and respiratory diseases
- Type
- article
- Field-Weighted Citation Impact
- 1.16